Euroapi SA (EAPI) AI Stock Analysis

• Market Cap: €248.75M
• Dividend Yield: N/A
• Average Volume (3M): 81.32K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.07
• Revenue Growth: -10.00%
• EPS Growth: 31.03%
• Country: FR
• Employees: 3,187
• Sector: Healthcare
• Sector Strength: 41
• Industry: Medical - Devices
• EPS (TTM): -1.38
• Shares Outstanding: 95,589,775
• 10 Day Avg. Volume: 58,114
• 30 Day Avg. Volume: 81,317
• PEG Ratio: -0.04
• Price to Book (P/B): 0.26
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 31.74
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €2.70
• Price Target Upside: 3.45% Upside
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 2

Euroapi SA is struggling financially, with declining revenue and negative profitability. Despite its stable equity position and low leverage, the company's valuation is poor due to negative earnings and lack of dividends. The technical indicators show no promising upward trends, reflecting overall challenges in the stock's performance.

Euroapi SA Business Overview & Revenue Model

Company Description

Euroapi SA develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use. The company was incorporated in 2021 and is based in Paris, France.

How the Company Makes Money

Euroapi SA generates revenue primarily through the production and sale of active pharmaceutical ingredients (APIs) to pharmaceutical companies and healthcare organizations. The company's revenue model is centered around its extensive portfolio of API products, which it supplies to various clients engaged in drug manufacturing and development. Euroapi benefits from long-term contracts and strategic partnerships with leading pharmaceutical companies that secure steady demand for its products. Additionally, the company invests in research and development to innovate and expand its product offerings, ensuring its competitiveness in the market and driving growth in its revenue streams.

Euroapi SA Financial Statement Overview

Summary

Euroapi SA is facing financial challenges, particularly in profitability and revenue growth. However, it demonstrates operational resilience with positive EBITDA margins and efficient cash flow generation. The balance sheet shows a strong equity position and low leverage, offering potential for recovery. Continued focus on managing costs and improving revenue is crucial.

Income Statement

Euroapi SA has faced declining revenue over the past year, with a negative revenue growth rate of 9.78% from 2023 to 2024. The company is experiencing significant challenges in profitability, as indicated by negative EBIT and net profit margins. The gross profit margin also reflects a downward trend. Despite these challenges, the company has managed to maintain a positive EBITDA margin, offering some stability in operational performance.

Balance Sheet

The balance sheet shows a moderate level of stability with a debt-to-equity ratio of 0.07, indicating low leverage. The return on equity is negative due to net losses, but the equity ratio remains healthy at 66.01%, suggesting a strong capital base. The company has been reducing its debt, which is a positive sign for future financial flexibility.

Cash Flow

Euroapi SA's cash flow remains a mixed picture with a significant improvement in operating cash flow from 2023 to 2024. However, the free cash flow growth rate is negative, reflecting high capital expenditures. The operating cash flow to net income ratio is positive, indicating efficient cash generation relative to net income, but the free cash flow to net income ratio is low.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
919.20M	1.02B	980.90M	892.80M	944.60M
	Gross Profit
142.40M	164.60M	176.90M	109.10M	90.50M
	EBIT
-120.40M	-234.30M	35.20M	300.00K	-24.00M
	EBITDA
-34.70M	71.00M	71.20M	62.40M	61.60M
	Net Income Common Stockholders
-130.60M	-189.70M	-15.10M	-15.80M	-6.30M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
73.00M	34.50M	74.50M	29.30M	153.90M
	Total Assets
1.49B	1.61B	1.74B	1.62B	1.60B
	Total Debt
69.10M	225.50M	120.80M	24.10M	73.40M
	Net Debt
-3.90M	191.00M	46.30M	13.80M	73.30M
	Total Liabilities
506.00M	684.70M	625.90M	607.00M	611.60M
	Stockholders Equity
983.50M	927.70M	1.11B	1.01B	989.40M
Cash Flow		Free Cash Flow
14.90M	-127.70M	-122.60M	-17.10M	8.40M
	Operating Cash Flow
122.90M	5.10M	44.80M	71.50M	96.80M
	Investing Cash Flow
-108.00M	-137.30M	-167.40M	-87.90M	-88.30M
	Financing Cash Flow
26.50M	92.20M	187.80M	26.50M	-8.40M

Euroapi SA Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.61
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:EAPI, the sentiment is Negative. The current price of 2.61 is below the 20-day moving average (MA) of 2.69, below the 50-day MA of 2.67, and below the 200-day MA of 3.30, indicating a bearish trend. The MACD of 0.02 indicates Positive momentum. The RSI at 43.88 is Neutral, neither overbought nor oversold. The STOCH value of 23.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:EAPI.

Euroapi SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$5.15B	3.02	-44.64%	2.82%	16.45%	-0.47%
EAPI	42 Neutral	€248.75M	―		―	-10.00%	31.03%